A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2
SARS-CoV-2 Infection
About this trial
This is an interventional prevention trial for SARS-CoV-2 Infection
Eligibility Criteria
Inclusion Criteria: Participants aged 18 to 65 years. Participants who have close contact with a SARS-CoV-2 infected individual (index case) are required to be randomized within 72 hours upon close contact. Willing and able to provide written informed consent, or with a legal representative who can provide informed consent. Exclusion Criteria: Have a history of severe allergy or hyper-sensitivity to inhaled allergen. Pregnant or breastfeeding women. Have participated, within the last 180 days prior to the screening, in a clinical study involving an investigational intervention of SARS-CoV-2 neutralizing antibody. Have other conditions not suitable for the study per investigator's discretion.
Sites / Locations
- Beijing Ditan Hospital,Capital Medical University
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Placebo Comparator
Placebo Comparator
Treatment Group 1
Treatment Group 2
Control Group 3
Control Group 4